At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active Controlled Trial, Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension Over a 3-Month Period, Followed by a 12-Month Follow-Up With Open-Label DE-130A Treatment.
In Brief
A Phase 3 clinical trial evaluating DE-130A, Xalatan®, and 2 other interventions for Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease. Completed, enrolled 386 participants across 1 site.
Detailed Summary
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a 3-Month period, followed by a 12-Month Follow-Up with Open-Label DE-130A Treatment.
Study Details
Timeline
Interventions
Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
After Week 12, received DE-130A continuously.
From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.